These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25940339)

  • 21. Optimization of estrogen receptor analysis by immunocytochemistry in random periareolar fine-needle aspiration samples of breast tissue processed as thin-layer preparations.
    Petroff BK; Clark JL; Metheny T; Xue Q; Kimler BF; Fabian CJ
    Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):360-4. PubMed ID: 16932030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical detection of estrogen and progesterone receptors performed with an antigen-retrieval technique on methacarn-fixed paraffin-embedded breast cancer tissues.
    Oyaizu T; Arita S; Hatano T; Tsubura A
    J Surg Res; 1996 Jan; 60(1):69-73. PubMed ID: 8592434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A reference image-based method for optimization of clinical immunohistochemistry.
    Kap M; Lam KH; Ewing-Graham P; Riegman P
    Histopathology; 2015 Aug; 67(2):193-205. PubMed ID: 25640638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
    Tang P; Tse GM
    Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Microfluidic Immunostaining System Enables Quality Assured and Standardized Immunohistochemical Biomarker Analysis.
    Kwon S; Cho CH; Kwon Y; Lee ES; Park JK
    Sci Rep; 2017 Apr; 7():45968. PubMed ID: 28378835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach.
    Dekker TJ; ter Borg S; Hooijer GK; Meijer SL; Wesseling J; Boers JE; Schuuring E; Bart J; van Gorp J; Bult P; Riemersma SA; van Deurzen CH; Sleddens HF; Mesker WE; Kroep JR; Smit VT; van de Vijver MJ
    Breast Cancer Res Treat; 2015 Jul; 152(2):247-52. PubMed ID: 26041687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry.
    Terry J; Torlakovic EE; Garratt J; Miller D; Köbel M; Cooper J; Bahzad S; Pilavdzic D; O'Malley F; O'Brien AE; SenGupta S; Alport E; Têtu B; Knight B; Pettigrew NM; Berendt R; Wolber R; Trotter MJ; Riddell RH; Gaboury L; Elms F; Magliocco A; Barnes P; Gown AM; Gilks CB
    Appl Immunohistochem Mol Morphol; 2009 Oct; 17(5):375-82. PubMed ID: 19363444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levey-Jennings Analysis Uncovers Unsuspected Causes of Immunohistochemistry Stain Variability.
    Vani K; Sompuram SR; Naber SP; Goldsmith JD; Fulton R; Bogen SA
    Appl Immunohistochem Mol Morphol; 2016; 24(10):688-694. PubMed ID: 26469328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
    Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
    Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proficiency testing of immunohistochemical biomarker assays in breast cancer.
    Wasielewski Rv; Hasselmann S; Rüschoff J; Fisseler-Eckhoff A; Kreipe H
    Virchows Arch; 2008 Dec; 453(6):537-43. PubMed ID: 18958494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
    Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
    J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting OncoDX recurrence scores with immunohistochemical markers: effect of stromelysin.
    Bradshaw SH; Pidutti D; Gravel DH; Song X; Robertson SJ
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):26-30. PubMed ID: 25153499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
    Zhu X; Ying J; Wang F; Wang J; Yang H
    Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling Canadian Quality Control Test Program for Steroid Hormone Receptors in Breast Cancer: Diagnostic Accuracy Study.
    Pérez T; Makrestsov N; Garatt J; Torlakovic E; Gilks CB; Mallett S
    Appl Immunohistochem Mol Morphol; 2016; 24(10):679-687. PubMed ID: 26200834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. External quality assessment for immunohistochemistry: experiences from NordiQC.
    Nielsen S
    Biotech Histochem; 2015 Jul; 90(5):331-40. PubMed ID: 25901597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone receptor expression in breast cancer: postanalytical issues.
    Lee M; Lee CS; Tan PH
    J Clin Pathol; 2013 Jun; 66(6):478-84. PubMed ID: 23526546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.